Chek2
M. musculus
checkpoint kinase 2
What the model saw
Gene: Chek2 Organism: Mus musculus Known functions: checkpoint kinase 2. serine/threonine-protein kinase Chk2. ATP binding. identical protein binding. kinase activity. protein homodimerization activity. protein kinase activity. protein kinase binding. protein serine kinase activity. protein serine/threonine kinase activity. ubiquitin protein ligase binding.
View unredacted entry
checkpoint kinase 2. serine/threonine-protein kinase Chk2. ATP binding. identical protein binding. kinase activity. protein homodimerization activity. protein kinase activity. protein kinase binding. protein serine kinase activity. protein serine/threonine kinase activity. ubiquitin protein ligase binding.
Solver output
CHEK2 (Checkpoint Kinase 2) is a central DNA damage response kinase that, upon activation by ATM following double-strand breaks, phosphorylates key substrates including p53 (stabilizing it), CDC25A/C (halting cell cycle progression), and BRCA1. While this activity is essential for tumor suppression, chronic or excessive CHK2 signaling drives irreversible cell cycle arrest and promotes cellular senescence, a hallmark of aging. In the context of aging, persistent DNA damage signaling through the ATM-CHEK2-p53 axis accelerates stem cell exhaustion and tissue dysfunction. Studies in mice have shown that loss of Chek2 can extend healthspan and delay age-related pathologies by reducing senescence burden, suggesting its normal pro-apoptotic/pro-senescence function is net anti-longevity. Additionally, CHEK2's role in ubiquitin ligase binding and p53 stabilization reinforces its function as a driver of cellular senescence rather than a promoter of survival and repair.
GenAge curators classify each gene's normal function as promoting (Pro-Longevity) or opposing (Anti-Longevity) longevity, based on synthesis across studies. Loss-of-function effects can vary from this depending on the manipulation.
Advisor judgment
The model predicted anti_longevity but the ground truth is pro_longevity. The model's reasoning is plausible on the surface (CHK2 drives senescence and apoptosis, which could be anti-longevity), but it gets the direction wrong. In mice, Chek2 loss has been associated with increased cancer susceptibility and reduced lifespan, while Chek2 activity supports genome integrity and tumor suppression, making it pro-longevity. The model incorrectly claims that "loss of Chek2 can extend healthspan and delay age-related pathologies by reducing senescence burden" — this is not well-supported and appears to be a hallucinated or misattributed finding. The model was fairly confident (0.72) in its wrong answer. The mechanistic framing (senescence as the primary driver) is also incorrect for this gene's longevity classification.
Raw API responses
solver
{
"reasoning": "CHEK2 (Checkpoint Kinase 2) is a central DNA damage response kinase that, upon activation by ATM following double-strand breaks, phosphorylates key substrates including p53 (stabilizing it), CDC25A/C (halting cell cycle progression), and BRCA1. While this activity is essential for tumor suppression, chronic or excessive CHK2 signaling drives irreversible cell cycle arrest and promotes cellular senescence, a hallmark of aging. In the context of aging, persistent DNA damage signaling through the ATM-CHEK2-p53 axis accelerates stem cell exhaustion and tissue dysfunction. Studies in mice have shown that loss of Chek2 can extend healthspan and delay age-related pathologies by reducing senescence burden, suggesting its normal pro-apoptotic/pro-senescence function is net anti-longevity. Additionally, CHEK2's role in ubiquitin ligase binding and p53 stabilization reinforces its function as a driver of cellular senescence rather than a promoter of survival and repair.",
"confidence": 0.72,
"key_pathways": [
"ATM-CHEK2-p53 DNA damage signaling",
"G1/S and G2/M cell cycle checkpoint arrest",
"cellular senescence induction"
],
"mechanism_class": "cellular_senescence",
"longevity_influence": "anti_longevity"
}advisor
{
"notes": "The model predicted anti_longevity but the ground truth is pro_longevity. The model's reasoning is plausible on the surface (CHK2 drives senescence and apoptosis, which could be anti-longevity), but it gets the direction wrong. In mice, Chek2 loss has been associated with increased cancer susceptibility and reduced lifespan, while Chek2 activity supports genome integrity and tumor suppression, making it pro-longevity. The model incorrectly claims that \"loss of Chek2 can extend healthspan and delay age-related pathologies by reducing senescence burden\" — this is not well-supported and appears to be a hallucinated or misattributed finding. The model was fairly confident (0.72) in its wrong answer. The mechanistic framing (senescence as the primary driver) is also incorrect for this gene's longevity classification.",
"failure_mode": "confident_wrong",
"answer_correct": false,
"mechanism_correct": false,
"reasoning_quality": 2,
"ground_truth_questionable": false
}